Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1_JR-FL in the setting of post-exposure prophylaxis in NOD/SCID/Jak3^-/- mice transplanted with human PBMCs.

ABSTRACT: Employing NOD/SCID/Jak3^-/- mice transplanted with human PBMCs (hNOJ mice) and replication-competent, red-fluorescent-protein (mCherry; mC)-labeled HIV-1_JR-FL (HIV_mC), we examined whether early antiretroviral treatment blocked the establishment of HIV-1 infection. The use of hNOJ mice and HIV_mC enabled us to visually locate infection foci and to examine the early dynamics of HIV_mC infection without using a large amount of antiretroviral unlike in non-human primate models. Although when raltegravir (RAL) administration was begun 1 day after intraperitoneal (ip) inoculation of HIV_mC, no plasma p24 or plasma HIV-1-RNA (pRNA) were detected in 10 of 12 hNOJ (hNOJ_mC^RAL+) mice as assessed on the last day of the

SUBMITTER: Ogata-Aoki H 

PROVIDER: S-EPMC8057117 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature